Hye-Sol Jung
Overview
Explore the profile of Hye-Sol Jung including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
45
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim M, Hong W, Kang H, Kim J, Lee D, Cheong J, et al.
Cell Death Dis
. 2025 Mar;
16(1):161.
PMID: 40055335
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor prognosis, largely due to the rapid development of chemoresistance in patients. Mitochondrial dynamics play a crucial role in cancer...
2.
Yun W, Kim T, Park S, Han Y, Choi G, Jung H, et al.
J Hepatobiliary Pancreat Sci
. 2025 Feb;
PMID: 40017377
Background: With the evolving treatment paradigms for pancreatic cancer, there is an increasing need for reliable markers to evaluate the effectiveness of preoperative chemotherapy. Due to the limitations of current...
3.
Park S, Choi G, Lee I, Seo Y, Chae Y, Yun W, et al.
Nutrients
. 2025 Feb;
17(4).
PMID: 40004975
Background: Pancreatic cancer is a highly aggressive malignancy with a poor prognosis. Neoadjuvant chemotherapy (NAC) is increasingly used to improve survival in patients with pancreatic cancer; however, it often results...
4.
Kim H, Kim W, Yun W, Jung H, Han Y, Lee M, et al.
Biomedicines
. 2025 Jan;
13(1.
PMID: 39857647
: Carbohydrate antigen 19-9 (CA19-9) is used as a marker to predict recurrence and survival of patients with pancreatic ductal adenocarcinoma (PDAC). Recently, fecal elastase-1 (FE-1) has been shown to...
5.
Yun W, Chae Y, Han Y, Jung H, Cho Y, Kang H, et al.
Ann Surg Oncol
. 2025 Jan;
32(4):2819-2829.
PMID: 39808212
Background: Benefits of neoadjuvant treatment for pancreatic cancer with major vessel invasion has been demonstrated through randomized controlled trials; however, the optimal neoadjuvant treatment strategy remains controversial, especially for radiotherapy....
6.
Lee M, Jung J, Han Y, Chae Y, Yun W, Jung H, et al.
Br J Surg
. 2024 Nov;
111(12).
PMID: 39602790
Background: Thoracic epidural analgesia (TEA), once the standard for pain management in major abdominal operations, is associated with postoperative complications, making preperitoneal continuous wound infiltration (CWI) a promising alternative. This...
7.
Lee M, Chae Y, Park S, Yun W, Jung H, Han Y, et al.
J Hepatobiliary Pancreat Sci
. 2024 Nov;
PMID: 39555959
Background: Pancreatoduodenectomy (PD) is a complex abdominal surgery, and the adoption of robotic PD has been on the rise because of its numerous benefits. This study aimed to investigate the...
8.
Yun W, Gil J, Choi H, Han Y, Jung H, Cho Y, et al.
Mol Imaging Biol
. 2024 Oct;
26(6):1068-1077.
PMID: 39365411
Purpose: Accurate clinical staging of potentially resectable pancreatic ductal adenocarcinoma (PDAC) is critical for establishing optimal treatment strategies. While the efficacy of fluorine-18-fluorodeoxyglucose ([F]FDG) positron emission tomography/computed tomography (PET/CT) in...
9.
Chae Y, Jung H, Yun W, Han Y, Cho Y, Lee M, et al.
Int J Surg
. 2024 Sep;
110(11):7150-7158.
PMID: 39311909
Background: R0 rates have increased as neoadjuvant treatment (NAT) has become the primary treatment for pancreatic ductal adenocarcinoma (PDAC) with venous involvement, suggesting a decrease in venous tumor infiltration. The...
10.
Jung H, Han Y, Chae Y, Yun W, Cho Y, Seo Y, et al.
Ann Surg
. 2024 Sep;
PMID: 39258374
Objective: To evaluate the diagnostic performance of surgical indications of the revised International Association of Pancreatology (IAP) 2023 guidelines compared to the IAP 2017 and European 2018 guidelines. Summary Background...